Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 141 articles: HTML format

Single Articles

October 2025
1. CHEN SC, Lee YT
   Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies.
   Clin Infect Dis. 2025 Oct 3:ciaf559. doi: 10.1093.
   PubMed    
   
   
   September 2025
2. RUIZ-TAGLE C, Seguel R, Villarroel L, Bernales M, et al
   Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial.
   Clin Infect Dis. 2025 Sep 26:ciaf526. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. CHEN SC, Chen CC
   Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases.
   Clin Infect Dis. 2025 Sep 25:ciaf536. doi: 10.1093.
   PubMed    
   
   
   
4. BROOKS MB, Lecca L, Becerra MC, Calderon RI, et al
   The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study.
   Clin Infect Dis. 2025 Sep 24:ciaf490. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. PEREZ-RECIO S, Grijota-Camino MD, Guardiola J, Juanola X, et al
   Prevention of Tuberculosis in Patients Treated With Biological Therapies: Twenty Years' Experience in a Specialised Tuberculosis Clinic in a Low-prevalence Country.
   Clin Infect Dis. 2025 Sep 5:ciaf491. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. ARRIAGA MB, Amorim G, Figueiredo MC, Staats C, et al
   Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts.
   Clin Infect Dis. 2025 Sep 3:ciaf475. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
7. LAW S, Fulcher I, Ashraf S, Bastard M, et al
   Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling.
   Clin Infect Dis. 2025 Aug 22:ciaf467. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. POORE H, Wambi P, Nkereuwem E, Nakafeero J, et al
   The three-gene Xpert Host Response signature for pediatric tuberculosis screening: A prospective diagnostic accuracy study.
   Clin Infect Dis. 2025 Aug 21:ciaf445. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. SINHA P, Bhargava M, Dauphinais MR, Carwile ME, et al
   In-kind Nutritional Supplementation for Persons With Drug-susceptible Tuberculosis and Their Household Contacts Would be Cost-effective for Reducing Tuberculosis Incidence and Mortality in Jharkhand, India: A Modeling Study.
   Clin Infect Dis. 2025 Aug 20:ciaf400. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. BISIMWA BC, Kiselinova M, Cuella I, Rigouts L, et al
    Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting.
    Clin Infect Dis. 2025 Aug 12:ciaf451. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. CHURCHYARD GJ, Swindells S, Gupta A, Shah NS, et al
    Preventing multidrug resistant tuberculosis: the dawn of a new era.
    Clin Infect Dis. 2025 Aug 7:ciaf426. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. CHELI S, Torre A, Schiuma M, Montrasio C, et al
    NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study.
    Clin Infect Dis. 2025;81:145-152.
    PubMed     Abstract available
    
    
    July 2025
13. MURRAY MB, Madden AE, Ofori SK
    Harmonization of Study Design and Reporting for Chronic Pulmonary Aspergillosis in Tuberculosis Patients.
    Clin Infect Dis. 2025 Jul 30:ciaf309. doi: 10.1093.
    PubMed    
    
    
    
14. BEZUIDENHOUT C, Long L, Nichols B, Meyer-Rath G, et al
    Sputum and tongue swab molecular testing for the in-home diagnosis of tuberculosis in unselected household contacts: a cost and cost-effectiveness analysis.
    Clin Infect Dis. 2025 Jul 24:ciaf389. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. LIU W, He T, Zhan S, Qin H, et al
    Safety, feasibility and rifapentine plasma concentration in Chinese children with 1 month of daily rifapentine plus isoniazid for tuberculosis infection.
    Clin Infect Dis. 2025 Jul 21:ciaf404. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. ROCKMAN L, Abdulgader SM, Minnies S, Palmer Z, et al
    Oral washes and tongue swabs for Xpert MTB/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum.
    Clin Infect Dis. 2025 Jul 18:ciaf397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. ANDREWS JR, Kendall EA, Cattamanchi A, Denkinger CM, et al
    Projecting the impact and costs of near point-of-care tuberculosis screening assays in community-based active case finding.
    Clin Infect Dis. 2025 Jul 17:ciaf395. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. MACLEAN EL, Pham YN, Pham CD, Nguyen BC, et al
    Long-term outcomes among people with multi-drug resistant tuberculosis in Vietnam: a prospective cohort study.
    Clin Infect Dis. 2025 Jul 9:ciaf363. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. LI Y, Zhang Y, Song L, Cai C, et al
    A Short, All-Oral Regimen for Pre-Extensively Drug-Resistant Tuberculosis: A Multicenter Open-label Single-arm Study.
    Clin Infect Dis. 2025 Jul 8:ciaf351. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. COX SR, Moe AH, Gupte AN, Kadam A, et al
    A point-of-care prediction tool for recurrent tuberculosis.
    Clin Infect Dis. 2025 Jul 8:ciaf353. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
21. LU X, Jiang Y, Zhang R, Zhang Y, et al
    Epidemiologic and Bacterial Factors Facilitating Long-Term Transmission of Multidrug-Resistant Tuberculosis in Shanghai, China.
    Clin Infect Dis. 2025 Jun 18:ciaf313. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. AGARWAL R, Nyendak M, Chava N, Allam RR, et al
    Long-term protection from TB preventive treatment among people with HIV in a high-burden tuberculosis setting: an observational cohort study from India.
    Clin Infect Dis. 2025 Jun 16:ciaf322. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. JAGANATH D, Nabeta P, Nicol MP, Castro R, et al
    Stool processing methods for Xpert Ultra testing in childhood tuberculosis: A prospective, multi-country accuracy study.
    Clin Infect Dis. 2025 Jun 3:ciaf289. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. DE JAGER V, Mockeliunas L, You H, Simonsson USH, et al
    A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination with Meropenem plus Amoxicillin/Clavulanate Among Adults with Rifampicin-Resistant Pulmonary Tuberculosis.
    Clin Infect Dis. 2025 Jun 2:ciaf276. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
25. PURCHASE SE, Brigden J, Seddon JA, Martinson NA, et al
    Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial.
    Clin Infect Dis. 2025 May 29:ciaf284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. BONGOMIN F, Denning DW
    Pulmonary Tuberculosis Associated Chronic Pulmonary Aspergillosis: Urgent Need to Standardize Reporting of Prevalence Studies.
    Clin Infect Dis. 2025 May 28:ciaf279. doi: 10.1093.
    PubMed    
    
    
    
27. 
    Correction to: Serial Mass Screening for Tuberculosis Among Incarcerated Persons in Brazil.
    Clin Infect Dis. 2025 May 21:ciaf223. doi: 10.1093.
    PubMed    
    
    
    
28. REGAN JJ, Wang Z, Phares CR
    The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the US Immigration Medical Examination: Are Vaccines Causing False-Negative Results?
    Clin Infect Dis. 2025 May 15:ciaf129. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. STADLER JAM, Kuhlin JJ, Molloy SF, Mtwa NN, et al
    Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis. 2025 May 9:ciaf112. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. CHIANG SS, Campbell JR, Pelissari DM, de Oliveira MCB, et al
    The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016-2022.
    Clin Infect Dis. 2025 May 6:ciaf233. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
31. LARSSON L, Calderwood CJ, Marambire ET, Held K, et al
    Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa.
    Clin Infect Dis. 2025 Apr 28:ciaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. DAHL VN, Pedersen OS, Butova T, Kuzhko M, et al
    Effectiveness of the BPaL(M) Regimen for Drug-Resistant Tuberculosis in Ukraine under Programmatic Conditions.
    Clin Infect Dis. 2025 Apr 25:ciaf214. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. KIM S, Pelissari DM, Harada LO, Sanchez M, et al
    Long-term mortality trends among individuals with tuberculosis: a retrospective cohort study of individuals diagnosed with tuberculosis in Brazil.
    Clin Infect Dis. 2025 Apr 18:ciaf206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. SUTHERLAND JS, van der Spuy GD, Shaw JA, Richardson T, et al
    Performance of 2 Finger-Stick Blood Tests to Triage Adults With Symptoms of Pulmonary Tuberculosis: A Prospective Multisite Diagnostic Accuracy Study.
    Clin Infect Dis. 2025 Apr 16:ciaf105. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. 
    Correction to: Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.
    Clin Infect Dis. 2025 Apr 4:ciaf174. doi: 10.1093.
    PubMed    
    
    
    
36. STEAD D, Wasserman S, Steenkamp E, Parrish A, et al
    Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa.
    Clin Infect Dis. 2025 Apr 2:ciaf080. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
37. BARTL L, Zeeb M, Kalin M, Loosli T, et al
    Machine Learning-Based Prediction of Active Tuberculosis in People with HIV using Clinical Data.
    Clin Infect Dis. 2025 Mar 25:ciaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. ADZEMOVIC T, Nalintya E, Fieberg A, Mande E, et al
    Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease.
    Clin Infect Dis. 2025 Mar 25:ciaf079. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. PRODANUK M, Silverberg SL, Piche-Renaud PP, Farrar DS, et al
    Adverse events of first-line therapy for pediatric tuberculosis: A systematic review and meta-analysis.
    Clin Infect Dis. 2025 Mar 24:ciaf152. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. MADDEN A, Ofori SK, Budu M, Sisay E, et al
    A systematic review of chronic pulmonary aspergillosis among patients treated for pulmonary tuberculosis.
    Clin Infect Dis. 2025 Mar 21:ciaf150. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. SODEKE O, Shah NS, Pals S, Riabokon S, et al
    Lower Tuberculosis Incidence Among People With Human Immunodeficiency Virus Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study.
    Clin Infect Dis. 2025 Mar 18:ciaf069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. SINGLA R, Khan S, Silsarma A, Chavan V, et al
    Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.
    Clin Infect Dis. 2025 Mar 13:ciaf068. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
44. JASWAL MR, Martinez L, Brooks M, Farooq S, et al
    Tuberculosis preventive treatment for household contacts at health facility and community settings in Pakistan.
    Clin Infect Dis. 2025 Feb 27:ciaf088. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. TZELIOS CA, Malatesta S, Carney T, White LF, et al
    Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis.
    Clin Infect Dis. 2025 Feb 20:ciae642. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. SINHA A, Klebe R, Rekart ML, Alvarez JL, et al
    The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
    Clin Infect Dis. 2025 Feb 18:ciaf035. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. MUNSIFF SS
    American Thoracic Society/Centers for Disease Control and Prevention/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Updated guideline on the treatment of tuberculosis.
    Clin Infect Dis. 2025 Feb 14:ciaf066. doi: 10.1093.
    PubMed    
    
    
    January 2025
48. MARANCHICK N, Peloquin CA, Haley CA
    Linezolid Dosing and Pharmacokinetics in North American Patients with Tuberculosis.
    Clin Infect Dis. 2025 Jan 21:ciaf027. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. ESPINOSA-PEREIRO J, Aguiar A, Nara E, Medina A, et al
    Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis.
    Clin Infect Dis. 2025 Jan 10:ciaf003. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. ARBIV OA, Holmes T, Kim MJ, Yan M, et al
    Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2025 Jan 9:ciaf004. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
51. MACPHERSON L, Kik SV, Quartagno M, Lakay F, et al
    Diagnostic Accuracy of Chest X-ray Computer-Aided Detection Software for Detection of Prevalent and Incident Tuberculosis in Household Contacts.
    Clin Infect Dis. 2024 Dec 18:ciae528. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. AUMA E, Alberts R, Derendinger B, Venter R, et al
    Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.
    Clin Infect Dis. 2024 Dec 12:ciae614. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. KHAN U, Rich M, Franke M, Lachenal N, et al
    The Frequency and Incidence of QT Prolongation with Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort.
    Clin Infect Dis. 2024 Dec 10:ciae601. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. ZHU Y, Forsman LD, Chen C, Zhang H, et al
    Reply to He et al: Established Association Between Glycemic Control and Anti-Tuberculosis Drug Exposures After Controlling Confounding Effects.
    Clin Infect Dis. 2024 Dec 9:ciae533. doi: 10.1093.
    PubMed    
    
    
    
55. CHEN J, Xie X, Zhang A, He Y, et al
    Is There a Genuine Correlation Between Blood Glucose Control and Anti-tuberculosis Drug Concentrations, or Is it Merely an Illusion?
    Clin Infect Dis. 2024 Dec 9:ciae532. doi: 10.1093.
    PubMed    
    
    
    November 2024
56. PUYAT JH, Brode SK, Shulha H, Romanowski K, et al
    Predicting risk of tuberculosis disease in people migrating to a low-TB incidence country: development and validation of a multivariable dynamic risk prediction model using health administrative data.
    Clin Infect Dis. 2024 Nov 20:ciae561. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. ROSEN LV, Thielking AM, Dugdale CM, Montepiedra G, et al
    Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks.
    Clin Infect Dis. 2024 Nov 15:ciae508. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. FERRAN E, Chan C, Sheikh N, Dedicoat M, et al
    Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017-2023.
    Clin Infect Dis. 2024 Nov 13:ciae560. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. PU J, Wu S, He JQ
    Efficacy and Safety of Systematic Corticosteroids treatment among HIV-Positive Patients with Tuberculosis: a systematic review and meta-analysis of randomized controlled trials.
    Clin Infect Dis. 2024 Nov 11:ciae563. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. CRITCHLEY JA, Limb ES, Khakharia A, Carey IM, et al
    Tuberculosis and increased incidence of cardiovascular disease: Cohort study using US and UK health records.
    Clin Infect Dis. 2024 Nov 4:ciae538. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
61. BROOKS JT, Solans BP, Beranger A, Schaaf HS, et al
    Linezolid Pharmacokinetic-Anemia Modeling in Children with Rifampicin-Resistant Tuberculosis.
    Clin Infect Dis. 2024 Oct 18:ciae497. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. NATHAVITHARANA RR, Pearl A, Biewer A, Young L, et al
    Effects of respiratory isolation for tuberculosis to reduce community-based transmission: a systematic review.
    Clin Infect Dis. 2024 Oct 14:ciae496. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. VIRDEE AK, Knudtzen FC, Llibre JM, Omland LH, et al
    Risk of tuberculosis after achieving HIV virological suppression on antiretroviral therapy: a Danish nationwide prospective cohort study.
    Clin Infect Dis. 2024 Oct 8:ciae499. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
64. SEIFERT M, Catanzaro DG, Gracia M, Hillery N, et al
    Prospective exploratory evaluation of Cepheid Xpert Mycobacterium tuberculosis host response cartridge: a focus on adolescents and young adults.
    Clin Infect Dis. 2024 Sep 5:ciae461. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
65. PADMAPRIYADARSINI C, Oswal VS, Jain CD, Mariappan MV, et al
    Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
    Clin Infect Dis. 2024 Aug 28:ciae388. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. BOSMAN S, Ayakaka I, Muhairwe J, Kamele M, et al
    Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa.
    Clin Infect Dis. 2024 Aug 27:ciae378. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
67. JARRETT BA, Shearer K, Motlhaoleng K, Chon S, et al
    Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With Human Immunodeficiency Virus in the North West Province of South Africa (the Teko Study): A Cl
    Clin Infect Dis. 2024 Jul 22:ciae268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. PRAKASH BABU S, Ezhumalai K, Raghupathy K, Karoly M, et al
    Factors associated with unfavourable treatment outcomes among persons with Pulmonary Tuberculosis: a multicentric prospective cohort study from India.
    Clin Infect Dis. 2024 Jul 11:ciae367. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. WANG MS, Li-Hunnam J, Chen YL, Gilmour B, et al
    Conversion or reversion of interferon gamma release assays for Mycobacterium tuberculosis infection: a systematic review and meta-analysis.
    Clin Infect Dis. 2024 Jul 2:ciae357. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
70. ZHU Y, Forsman LD, Chen C, Zhang H, et al
    Drug exposure and treatment outcomes in patients with multidrug resistant tuberculosis and diabetes mellitus: A multicenter prospective cohort study from China.
    Clin Infect Dis. 2024 Jun 24:ciae329. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. RICHTERMAN A, Saintilien E, St-Cyr M, Claudia Gracia L, et al
    Food Insecurity at Tuberculosis Treatment Initiation Is Associated With Clinical Outcomes in Rural Haiti: A Prospective Cohort Study.
    Clin Infect Dis. 2024 Jun 18:ciae252. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. RASHITOV M, Franke M, Trevisi L, Bekbolatova G, et al
    Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
    Clin Infect Dis. 2024 Jun 4:ciae305. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. ABBOTT R, Landsiedel K, Atukunda M, Puryear SB, et al
    Incident Tuberculosis Infection is Associated with Alcohol use in Adults in Rural Uganda.
    Clin Infect Dis. 2024 Jun 2:ciae304. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
74. BURKE RM, Nyirenda SK, Mtenga T, Twabi HH, et al
    Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine LAM in adults with HIV admitted to hospital (CASTLE study): A cluster randomised trial.
    Clin Infect Dis. 2024 May 15:ciae273. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. SHAH NS, Kityo C, Hughes MD, McCarthy C, et al
    Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
    Clin Infect Dis. 2024 May 13:ciae269. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
76. SINHA P, Ezhumalai K, Du X, Ponnuraja C, et al
    Undernourished Household Contacts Are at Increased Risk of Tuberculosis (TB) Disease, but not TB Infection- a Multicenter Prospective Cohort Analysis.
    Clin Infect Dis. 2024 Apr 23:ciae149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. FARHAT MR, Jacobson KR
    For Tuberculosis, Not "To Screen or Not to Screen?" but "Who?" and "How?".
    Clin Infect Dis. 2024 Apr 18:ciae058. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. GOSWAMI N, Reed C
    Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for Deisolation in Community Settings.
    Clin Infect Dis. 2024 Apr 18:ciae198. doi: 10.1093.
    PubMed    
    
    
    
79. SHAH M, Dansky Z, Nathavitharana R, Behm H, et al
    NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings.
    Clin Infect Dis. 2024 Apr 18:ciae199. doi: 10.1093.
    PubMed    
    
    
    
80. MARINER-LLICER C, Saavedra Cervera B, Mambuque E, Gomes N, et al
    Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.
    Clin Infect Dis. 2024;78:842-845.
    PubMed     Abstract available
    
    
    
81. MIKIASHVILI L, Kempker RR, Chakhaia TS, Bablishvili N, et al
    Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Clin Infect Dis. 2024;78:1043-1052.
    PubMed     Abstract available
    
    
    
82. CHABALA C, Wobudeya E, van der Zalm MM, Kapasa M, et al
    Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial.
    Clin Infect Dis. 2024 Apr 9:ciae193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. RODRIGUEZ-MOLINO P, Tebruegge M, Noguera-Julian A, Neth O, et al
    Tuberculosis disease in immunocompromised children and adolescents: a pTBnet multi-centre case-control study.
    Clin Infect Dis. 2024 Apr 3:ciae158. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. PODANY AT, Cramer Y, Imperial M, Rosenkranz SL, et al
    Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
    Clin Infect Dis. 2024 Apr 3:ciae183. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
85. BERTUMEN JB, Pascopella L, Han E, Glenn-Finer R, et al
    Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection-California, 2016-2020.
    Clin Infect Dis. 2024 Mar 26:ciae169. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. MORGAN H, Ndjeka N, Hasan T, Gegia M, et al
    Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: A retrospective cohort study.
    Clin Infect Dis. 2024 Mar 25:ciae145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. SUNSTRUM J, Power LE, Fligiel HM, Lauter C, et al
    Human Disease due to Mycobacterium bovis Linked to Free-Ranging Deer in Michigan.
    Clin Infect Dis. 2024;78:637-645.
    PubMed     Abstract available
    
    
    
88. KRISHNAN S, Chaisson RE
    US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
    Clin Infect Dis. 2024;78:514-517.
    PubMed     Abstract available
    
    
    
89. NGO HX, Xu AY, Velasquez GE, Zhang N, et al
    Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
    Clin Infect Dis. 2024 Mar 11:ciae119. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
90. CROCKER-BUQUE T, Lachenal N, Narasimooloo C, Abdrasuliev T, et al
    Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
    Clin Infect Dis. 2024 Feb 29:ciad767. doi: 10.1093.
    PubMed    
    
    
    
91. TEIXEIRA LAA, Santos B, Correia MG, Valiquette C, et al
    Long-term protective effect of tuberculosis preventive therapy in a medium/high TB incidence setting.
    Clin Infect Dis. 2024 Feb 26:ciae101. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. WHITE YN, Solans BP, Denti P, van der Laan LE, et al
    Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    Clin Infect Dis. 2024 Feb 10:ciae024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. PIVETTA DE ARAUJO RC, Martinez L, da Silva Santos A, Ferreira Lemos E, et al
    Serial Mass Screening for Tuberculosis among Incarcerated Persons in Brazil.
    Clin Infect Dis. 2024 Feb 7:ciae055. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. STEADMAN A, Andama A, Ball A, Mukwatamundu J, et al
    New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics.
    Clin Infect Dis. 2024 Feb 2:ciae041. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
95. MARQUEZ C, Atukunda M, Nugent J, Charlebois ED, et al
    Community-Wide Universal Human Immunodeficiency Virus (HIV) Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial.
    Clin Infect Dis. 2024 Jan 16:ciad776. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. KU JH, Fischer H, Qian LX, Li K, et al
    Latent tuberculosis infection testing practices in a large U.S. integrated healthcare system.
    Clin Infect Dis. 2024 Jan 11:ciae015. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. GARCIA LS, Costa AG, Araujo-Pereira M, Spener-Gomes R, et al
    The Xpert(R) MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort.
    Clin Infect Dis. 2024 Jan 3:ciad794. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. LINDE L, Brooks MB, Martinez L
    Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission.
    Clin Infect Dis. 2024 Jan 3:ciad791. doi: 10.1093.
    PubMed    
    
    
    December 2023
99. LIN KY, Sun HY, Yang CJ, Lu PL, et al
    Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV.
    Clin Infect Dis. 2023 Dec 5:ciad730. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
100. SCHWALB A, Kayumba K, Houben RMGJ, Bothamley GH, et al
     Recent travel and tuberculosis in migrants: data from a low incidence country.
     Clin Infect Dis. 2023 Nov 6:ciad672. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. LIU X, Xia L, Wang X, Huang Z, et al
     Treatment Outcomes in Multidrug-Resistant Tuberculosis During Pregnancy.
     Clin Infect Dis. 2023 Nov 1:ciad594. doi: 10.1093.
     PubMed    
     
     
     October 2023
102. BROWN TS, Tang L, Omar SV, Joseph L, et al
     Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.
     Clin Infect Dis. 2023 Oct 24:ciad596. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. HASAN T, Medcalf E, Nyang'wa BT, Egizi E, et al
     The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis.
     Clin Infect Dis. 2023 Oct 24:ciad653. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. KHAN AR, Tirlangi PK, Wig N, Soneja M, et al
     Immortal Time Bias for Infliximab in Central Nervous System Tuberculosis.
     Clin Infect Dis. 2023 Oct 13:ciad590. doi: 10.1093.
     PubMed    
     
     
     
105. SUNG J, Nantale M, Nalutaaya A, Biche P, et al
     Evidence for tuberculosis in individuals with Xpert Ultra "trace" sputum during screening of high-burden communities.
     Clin Infect Dis. 2023 Oct 3:ciad595. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2023
106. SAUER SM, Mitnick CD, Khan U, Hewison C, et al
     Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.
     Clin Infect Dis. 2023 Sep 29:ciad589. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. GUPTA A, Hughes MD, Cruz JL, Avihingsanon A, et al
     Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester.
     Clin Infect Dis. 2023 Sep 28:ciad583. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. KASAIE P, Pennington J, Gupta A, Dowdy DW, et al
     The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates.
     Clin Infect Dis. 2023 Sep 19:ciad557. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. BOAST A, How JA, Lau C, Sett A, et al
     Pre-XDR congenital tuberculosis in an extremely premature baby.
     Clin Infect Dis. 2023 Sep 8:ciad540. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2023
110. BRUMMER LE, Thompson RR, Malhotra A, Shrestha S, et al
     Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis.
     Clin Infect Dis. 2023 Aug 25:ciad501. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. LOTIA FARRUKH I, Lachenal N, Adenov MM, Ahmed S, et al
     Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
     Clin Infect Dis. 2023 Aug 22:ciad445. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. SULIMAN S, Jaganath D, DiNardo A
     Predicting Pediatric Tuberculosis: The Need for Age-Specific Host Biosignatures.
     Clin Infect Dis. 2023;77:450-452.
     PubMed    
     
     
     
113. WALLES J, Winqvist N, Hansson SR, Sturegard E, et al
     Pregnancy outcomes in women screened for tuberculosis infection in Swedish antenatal care.
     Clin Infect Dis. 2023 Aug 12:ciad465. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. BROUGH J, Martinez L, Hatherill M, Zar HJ, et al
     Public health impact and cost-effectiveness of screening for active tuberculosis disease or infection among children in South Africa.
     Clin Infect Dis. 2023 Aug 5:ciad449. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2023
115. HU Z, Liu K, Zhou M, Jiang X, et al
     Mass tuberculosis screening among the elderly: A population-based study in a well-confined rural county in eastern China.
     Clin Infect Dis. 2023 Jul 28:ciad438. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. WINGFIELD T
     Ending tuberculosis in older people: new strategies for an age-old disease.
     Clin Infect Dis. 2023 Jul 28:ciad439. doi: 10.1093.
     PubMed    
     
     
     
117. ACUNA-VILLAORDUNA C, Fennelly KP, Jones-Lopez EC
     Aerosol Sampling Outperforms Sputum to Predict Mycobacterium tuberculosis Transmission.
     Clin Infect Dis. 2023 Jul 18:ciad372. doi: 10.1093.
     PubMed    
     
     
     
118. S AM, Gautam P, D SSK, Mannam P, et al
     Effectiveness of adjunctive high dose infliximab therapy to improve disability free survival among patients with severe CNS tuberculosis: a matched retrospective cohort study.
     Clin Infect Dis. 2023 Jul 5:ciad401. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2023
119. MOON SM, Choi H, Kim SH, Kang HK, et al
     Increased lung cancer risk and associated risk factors in tuberculosis survivors: A Korean population-based study.
     Clin Infect Dis. 2023 Jun 22:ciad373. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. LUCZYNSKI P, Holmes T, Romanowski K, Arbiv OA, et al
     Risk of tuberculosis disease in people with chronic kidney disease without kidney failure: A systematic review and meta-analysis.
     Clin Infect Dis. 2023 Jun 13:ciad364. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. IWASE SC, Edlefsen PT, Bhebhe L, Motsumi K, et al
     T-SPOT.TB reactivity in Southern African children with and without in utero HIV exposure.
     Clin Infect Dis. 2023 Jun 9:ciad356. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. SOLANS BP, Imperial MZ, Olugbosi M, Savic RM, et al
     Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
     Clin Infect Dis. 2023;76:1903-1910.
     PubMed     Abstract available
     
     
     May 2023
123. ZEEB M, Tepekule B, Kusejko K, Reiber C, et al
     Understanding the decline of incident, active tuberculosis in people with HIV in Switzerland.
     Clin Infect Dis. 2023 May 31:ciad330. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. HALEY CA, Schechter MC, Ashkin D, Peloquin CA, et al
     Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease.
     Clin Infect Dis. 2023 May 30:ciad312. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. AHSBERG J, Puplampu P, Kwashie A, Commey JO, et al
     Point-of-care urine LAM testing to guide tuberculosis treatment among severely ill in-patients with HIV in real-world practice: a multi-center stepped wedge cluster-randomized trial from Ghana.
     Clin Infect Dis. 2023 May 26:ciad316. doi: 10.1093.
     PubMed     Abstract available
     
     
     
126. KRISHNAN S, Wu X, Kim S, McIntire K, et al
     One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis.
     Clin Infect Dis. 2023 May 25:ciad301. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. ROMANOWSKI K, Law MR, Karim ME, Campbell JR, et al
     Healthcare utilization after respiratory tuberculosis: a controlled interrupted time series analysis.
     Clin Infect Dis. 2023 May 9:ciad290. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. BOBAK CA, Botha M, Workman L, Hill JE, et al
     Gene expression in cord blood and tuberculosis in early childhood: A nested case-control study in a South African birth cohort.
     Clin Infect Dis. 2023 May 5:ciad268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. TIMIRE C, Pedrazzoli D, Boccia D, Houben RM, et al
     Use of a sustainable livelihood framework-based measure to estimate socioeconomic impact of tuberculosis on house-holds.
     Clin Infect Dis. 2023 May 3:ciad273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. LOUIE JK, Keh C
     Latent Tuberculosis Infection Treatment: Still a Long Road Ahead.
     Clin Infect Dis. 2023 May 1:ciad251. doi: 10.1093.
     PubMed    
     
     
     
131. MELNYCHUK L, Perlman-Arrow S, Bastos M, Menzies D, et al
     A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events.
     Clin Infect Dis. 2023 May 1:ciad246. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2023
132. BURKE RM, Nliwasa M, Dodd PJ, Feasey HR, et al
     Impact of community-wide tuberculosis active case finding and HIV testing on tuberculosis trends in Malawi.
     Clin Infect Dis. 2023 Apr 26:ciad238. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. CHAISSON LH
     Finding tuberculosis: More evidence for community-wide systematic screening.
     Clin Infect Dis. 2023 Apr 26:ciad232. doi: 10.1093.
     PubMed    
     
     
     
134. HUSSAIN H, Jaswal M, Farooq S, Safdar N, et al
     Scale up of rifapentine-isoniazid (3HP) for tuberculosis prevention amongst household contacts in two urban centers: An effectiveness assessment.
     Clin Infect Dis. 2023 Apr 21:ciad245. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. SABET N, Omar T, Milovanovic M, Magajane T, et al
     Undiagnosed pulmonary TB and COVID in adults dying at home in a high TB burden setting, before and during pandemic COVID-19: an autopsy study.
     Clin Infect Dis. 2023 Apr 12:ciad212. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2023
136. UPTON CM, Wiesner L, Dooley KE, Maartens G, et al
     Cerebrospinal Fluid and Tuberculosis Meningitis.
     Clin Infect Dis. 2023 Mar 29:ciad186. doi: 10.1093.
     PubMed    
     
     
     
137. ALLARD-GRAY A, Boakye I, Camara A, Eisenbeis L, et al
     Factors Associated with Discontinuation of Tuberculosis Preventive Treatment: Post-Hoc Analysis of Two Randomized Controlled Trials.
     Clin Infect Dis. 2023 Mar 23:ciad164. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. BONNET M, Gabillard D, Domoua S, Muzoora C, et al
     High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF(R) for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV.
     Clin Infect Dis. 2023 Mar 8:ciad125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. LIU Q, You N, Wen J, Wang J, et al
     Yield and efficiency of a population-based mass tuberculosis screening intervention among persons with diabetes in Jiangsu Province, China.
     Clin Infect Dis. 2023 Mar 3:ciad118. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2022
140. DAVIS AG, Wasserman S, Stek C, Maxebengula M, et al
     A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis (The LASER-TBM Trial).
     Clin Infect Dis. 2022 Dec 9:ciac932. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2022
141. DAVIS AG, Dreyer AJ, Albertyn C, Maxebengula M, et al
     Cognitive Impairment in Tuberculous Meningitis.
     Clin Infect Dis. 2022 Oct 20. pii: 6763738. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.